Article
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Annals of hematology - 1 Jul 2017
Vannucchi Alessandro Maria, Verstovsek Srdan, Guglielmelli Paola, Griesshammer Martin, Burn Timothy C, Naim Ahmad, Paranagama Dilan, Marker Mahtab, Gadbaw Brian, Kiladjian Jean-Jacques
Abstract excerpt
In patients with polycythemia vera (PV), an elevated JAK2 p.V617F allele burden is associated with indicators of more severe disease (e.g., leukocytosis, splenomegaly, and increased thrombosis risk); however, correlations between allele burden reductions and clinical benefit in patients with PV have not been extensively evaluated in a randomized trial. This exploratory analysis from the multicenter, open-label,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.